Knight Therapeutics Inc. (TSE:GUD - Get Free Report) was down 6.4% during trading on Thursday . The stock traded as low as C$5.50 and last traded at C$5.68. 132,436 shares changed hands during trading, an increase of 95% from the average daily volume of 68,069 shares. The stock had previously closed at C$6.07.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the company. Canaccord Genuity Group set a C$6.50 target price on Knight Therapeutics and gave the company a "buy" rating in a report on Friday. Stifel Nicolaus lifted their target price on shares of Knight Therapeutics from C$6.25 to C$7.45 and gave the company a "buy" rating in a research note on Tuesday, March 25th. Finally, Research Capitl upgraded Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 11th. Two investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Strong Buy" and a consensus target price of C$7.15.
Check Out Our Latest Analysis on GUD
Knight Therapeutics Stock Up 0.5 %
The firm has a market cap of C$577.57 million, a price-to-earnings ratio of -19.06, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The company has a debt-to-equity ratio of 7.52, a current ratio of 3.36 and a quick ratio of 1.79. The firm has a 50 day moving average price of C$5.89 and a 200-day moving average price of C$5.60.
Insider Buying and Selling at Knight Therapeutics
In other news, insider Sime Armoyan acquired 17,600 shares of Knight Therapeutics stock in a transaction on Tuesday, March 4th. The shares were purchased at an average cost of C$5.48 per share, for a total transaction of C$96,488.48. Over the last quarter, insiders have sold 3,143,300 shares of company stock valued at $19,733,740. 45.62% of the stock is currently owned by corporate insiders.
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
See Also
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
